Oncology Pharma (PK) Stock Price - ONPH

-0.0004 (-4.21%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncology Pharma Inc (PK) ONPH OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0004 -4.21% 0.0091 0.0066 0.0119 0.0066 0.0095 16:25:07
Bid Price Ask Price Spread Spread % News
0.001 0.02 0.019 95.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
32 454,238 $ 0.009286 $ 4,218 736,986 0.003 - 0.10
Last Trade Time Type Quantity Stock Price Currency
15:49:08 2,875 $ 0.0091 USD

Oncology Pharma (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.37M 150.15M 19.93M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
7.25k $ - 0.00% - -

more financials information »

Oncology Pharma (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0120.0130.00660.0097476655,481-0.0029-24.17%
1 Month0.0350.04250.00660.02223961,763,866-0.0259-74.0%
3 Months0.020.04450.00660.0252451777,810-0.0109-54.5%
6 Months0.0250.060.00660.0250192447,921-0.0159-63.6%
1 Year0.010.100.0030.0305689348,919-0.0009-9.0%
3 Years0.010.100.0030.0305689348,919-0.0009-9.0%
5 Years0.010.100.0030.0305689348,919-0.0009-9.0%

Oncology Pharma (PK) Description

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The Company has assembled a team of executives and advisors with a proven multi-disciplinary expertise in the field of cancer therapies and leadership to identify, negotiate and amalgamate "best in class" research, technologies, and drug delivery that are synergistic and collaborative. Oncology Pharma has executed Letters of Intent with Kalos Therapeutics, with its lead anti-cancer bio-pharmaceutical (a peptide) medication, KTH-222. NanoSmart Pharmaceuticals' drug delivery platform can target many types of cancer and other diseases. Connect2Med, a powerful application used for recruiting, enrolling and supporting patients for clinical trials. Finally, the Company has entered into a Letter of Intent to acquire a 50% stake in Diagnomics, Inc., which is a "cutting edge" molecular diagnostic company in precision medicine, a CLIA and CAP accredited Laboratory that among other uses provides services to global pharmaceutical companies, including academic and biotech companies in San Diego, CA. Diagnomics' use of pharmacogenetics combined with artificial intelligence is a "game changer" in precision medicine, drug development, clinical trials, lowering of cost and time of clinical trials, a faster regulatory approval process and faster availability of drugs to the patients. Further information may be found at www.oncology-pharma.com.

Your Recent History
Oncology P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.